<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02287818</url>
  </required_header>
  <id_info>
    <org_study_id>AC-201-GOU-002</org_study_id>
    <nct_id>NCT02287818</nct_id>
  </id_info>
  <brief_title>A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>TWi Biotechnology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TWi Biotechnology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      AC-201CR is a control released formulation of AC-201 that in previous clinical studies showed
      potential dual effects in both reducing serum uric acid (sUA) and gout flares. The mechanism
      of actions of AC-201 include the inhibition of the production and activity of caspase-1 and
      interleukin-1β (IL-1β), and selective inhibition of re-absorption transporters in kidney. The
      goal of gout treatment is to reduce serum uric acid (sUA) concentrations below the urate
      solubility limit while avoiding acute gout flares. However, the initiation of urate-lowering
      therapy (ULT) increases the occurrence of acute gouty arthritis flares. IL-1β plays a key
      role in mediating this inflammatory response. The study is designed to test the
      urate-lowering effect, safety, and tolerability of AC-201CR in an initial dosing period,
      followed by addition of an ULT to test the efficacy and safety of the combination and
      prophylaxis of gout flares during ULT.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">October 27, 2016</completion_date>
  <primary_completion_date type="Actual">October 27, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Subjects Achieving Serum Uric Acid Concentration &lt;6.0 mg/dL</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">127</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo plus Febuxostat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AC-201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AC-201 CR tablet plus Febuxostat</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo twice daily from Day 1 to Week 12</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>PBO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-201</intervention_name>
    <description>AC-201 CR tablet 100 mg twice daily from Day 1 to Week 12</description>
    <arm_group_label>AC-201</arm_group_label>
    <other_name>AC-201 CR tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat</intervention_name>
    <description>Febuxostat 40 mg once daily from Week 4 to Week 16; titration to 80 mg once daily at Week 8 as needed to achieve serum uric acid concentration &lt;6 mg/dL</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>AC-201</arm_group_label>
    <other_name>ULT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female age 20 to 65 years, inclusive.

          2. Meets ≥6 of the 12 American College of Rheumatology preliminary criteria (1977) for
             the classification of acute arthritis of primary gout (Appendix 2), OR have proven
             tophus or documented monosodium urate (MSU) crystals in the joint fluid.

          3. Serum uric acid ≥7.5 mg/dL and ≤10 mg/dL at screening with ≥1 gouty arthritis flare
             within one year prior to screening, OR serum uric acid ≥9 mg/dL and ≤10 mg/dL at
             screening with or without prior gout flares.

        Exclusion Criteria:

          1. Use of allopurinol, febuxostat, benzbromarone, probenecid, or sulfinpyrazone within 2
             weeks prior to screening.

          2. Occurrence of a gouty arthritis flare within 1 week prior to screening or during the
             screening period through baseline.

          3. Use of colchicine within 1 week prior to screening.

          4. Use of Glucocorticoids, NSAIDs or COX-2 inhibitors within 1 week prior to screening.

          5. Allergy, contraindication, or intolerance to febuxostat.

          6. Severe renal impairment.

          7. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) concentration &gt;2
             times the upper limit of laboratory normal range (&gt;2x ULN) at screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chang-Youh Tsai</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Veteran General Hospital (TVGH)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taipei Veteran General Hospital (TVGH)</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2014</study_first_submitted>
  <study_first_submitted_qc>November 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2014</study_first_posted>
  <last_update_submitted>April 5, 2017</last_update_submitted>
  <last_update_submitted_qc>April 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Febuxostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

